GCP
MDGL icon

Garda Capital Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Garda Capital Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-702
Closed -$212K – 277
2025
Q2 		$212K Buy
+702
New +$209K 0.01% 537
2023
Q2 		– Sell
-140
Closed -$33.9K – 433
2023
Q1 		$33.9K Buy
+140
New +$38.1K ﹤0.01% 341

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Garda Capital Partners's MDGL Position: Q3 2025 in Review

Garda Capital Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2025, closing a stake of 702 shares — an estimated $212K sold.

Garda Capital Partners first reported a position in MDGL in Q1 2023 and held it in 2 quarters. The position peaked at $212K in Q2 2025. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Garda Capital Partners reported no remaining Madrigal Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Garda Capital Partners sold 702 Madrigal Pharmaceuticals shares in Q3 2025, an estimated $212K.
  • Garda Capital Partners first reported a position in Madrigal Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Garda Capital Partners's Madrigal Pharmaceuticals position peaked at $212K in Q2 2025.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Garda Capital Partners's 13F filing for Q3 2025, filed 10 Nov 2025.